AVIR logo

Atea Pharmaceuticals (AVIR) Company Overview

Profile

Full Name:

Atea Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 30, 2020

Indexes:

Not included

Description:

Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral therapies. They aim to create innovative treatments for viral infections, particularly COVID-19. Their research combines advanced technology and scientific expertise to improve patient outcomes and address unmet medical needs in infectious diseases.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Aug 13, 24 Morgan Stanley
Equal-Weight
Aug 10, 23 JP Morgan
Underweight
Mar 16, 23 JP Morgan
Neutral
Jan 27, 23 SVB Leerink
Market Perform
Jan 24, 23 Morgan Stanley
Underweight
Aug 15, 22 Morgan Stanley
Underweight
Mar 2, 22 JP Morgan
Neutral
Mar 1, 22 SVB Leerink
Market Perform
Feb 16, 22 SVB Leerink
Market Perform
Jan 6, 22 Morgan Stanley
Underweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process
Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process
Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process
AVIR
businesswire.comDecember 18, 2024

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with their affiliates, the “Concerned Shareholder Group” or “we”), who collectively own approximately 3% of the outstanding shares of Atea Pharmaceuticals (NASDAQ: AVIR) (“Atea” or the “Company”), today issued the following open letter to the Company's Board of Directors: *** December 18, 2024 Board of Directors (the “Board”) Atea Pharmaceuticals, Inc. 225 Franklin Street, Suit.

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
AVIR
globenewswire.comDecember 16, 2024

BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged Evercore, a global independent investment bank, to identify potential opportunities to enhance shareholder value, including the exploration of strategic partnerships related to its Phase 3-ready program for the treatment of hepatitis C virus (HCV).

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
AVIR
benzinga.comDecember 4, 2024

On Wednesday, Atea Pharmaceuticals, Inc. AVIR released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling and can lead to serious liver damage.

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
AVIR
globenewswire.comDecember 4, 2024

Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
AVIR
globenewswire.comNovember 15, 2024

BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for the treatment of HCV. These data are being presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
AVIR
seekingalpha.comNovember 9, 2024

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Jonae Barnes - SVP of Investor Relations and Corporate Communications Dr. Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Dr. Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Dr. Arantxa Horga - Chief Medical Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Isabella Camaj - JPMorgan Andy Hsieh - William Blair Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
AVIR
globenewswire.comOctober 30, 2024

BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced three upcoming poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for HCV. These data will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
AVIR
zacks.comOctober 16, 2024

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
AVIR
zacks.comSeptember 30, 2024

Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
AVIR
zacks.comAugust 28, 2024

Here is how Atea Pharmaceuticals, Inc. (AVIR) and McKesson (MCK) have performed compared to their sector so far this year.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Atea Pharmaceuticals?
  • Does Atea Pharmaceuticals pay dividends?
  • What sector is Atea Pharmaceuticals in?
  • What industry is Atea Pharmaceuticals in?
  • What country is Atea Pharmaceuticals based in?
  • When did Atea Pharmaceuticals go public?
  • Is Atea Pharmaceuticals in the S&P 500?
  • Is Atea Pharmaceuticals in the NASDAQ 100?
  • Is Atea Pharmaceuticals in the Dow Jones?
  • When was Atea Pharmaceuticals's last earnings report?
  • When does Atea Pharmaceuticals report earnings?
  • Should I buy Atea Pharmaceuticals stock now?

What is the ticker symbol for Atea Pharmaceuticals?

The ticker symbol for Atea Pharmaceuticals is NASDAQ:AVIR

Does Atea Pharmaceuticals pay dividends?

No, Atea Pharmaceuticals does not pay dividends

What sector is Atea Pharmaceuticals in?

Atea Pharmaceuticals is in the Healthcare sector

What industry is Atea Pharmaceuticals in?

Atea Pharmaceuticals is in the Biotechnology industry

What country is Atea Pharmaceuticals based in?

Atea Pharmaceuticals is headquartered in United States

When did Atea Pharmaceuticals go public?

Atea Pharmaceuticals's initial public offering (IPO) was on October 30, 2020

Is Atea Pharmaceuticals in the S&P 500?

No, Atea Pharmaceuticals is not included in the S&P 500 index

Is Atea Pharmaceuticals in the NASDAQ 100?

No, Atea Pharmaceuticals is not included in the NASDAQ 100 index

Is Atea Pharmaceuticals in the Dow Jones?

No, Atea Pharmaceuticals is not included in the Dow Jones index

When was Atea Pharmaceuticals's last earnings report?

Atea Pharmaceuticals's most recent earnings report was on Nov 7, 2024

When does Atea Pharmaceuticals report earnings?

The next expected earnings date for Atea Pharmaceuticals is Feb 28, 2025

Should I buy Atea Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions